EW Price Prediction Next Week
Based on the provided data and technical analysis, here is the prediction for EW's stock price next week:
Technical Analysis
Price Levels and Indicators
- Current Fibonacci levels show key resistance at $73.10 and support at $68.61
- RSI at 34.29 indicates oversold conditions
- MACD at -0.96 shows bearish momentum
- Price trading below both 20-day MA (72.27) and 200-day MA (76.10) indicates bearish trend
Recent News Impact The most significant recent news is that Katie Szyman, who previously headed Edwards Lifesciences' critical care division, has been appointed as CEO of Masimo. This personnel movement suggests stability in Edwards' management team as they were able to successfully develop internal talent.
Price Prediction Based on technical indicators and recent news:
- Short-term resistance: $73.10
- Support level: $68.61
- Target price range for next week: $69.50-$71.50
Trading Recommendation SELL with the following rationale:
- Price trading below key moving averages indicates bearish trend
- Negative MACD suggests continued downward momentum
- While RSI shows oversold conditions, the overall technical setup remains bearish
- Price likely to test support at $68.61 before any significant bounce
Set stop-loss above resistance at $73.50 to manage risk.
EW Similar Chart Price Prediction
The price of EW is predicted to go up 2.22%, based on the high correlation periods with RYAM. The similarity of these two price pattern on the periods is 97.17%.
EW
RYAM
Up: 2.22%Similarity: 97.17%
EW Revenue Forecast
EW EPS Forecast
EW FAQs
What is revenue forecast for next quarter？
What is eps forecast for next quarter？
EW VS S&P500
Edwards' efforts to focus on efficiency and higher-margin products have paid off, as gross margins increased from 47% in 2000 to 77% in 2023.
Cardiothoracic surgeons are a fairly conservative bunch and like to stick with proven devices and brands. As a pioneer in heart valves, Edwards continues to be seen as the gold standard.
Edwards should benefit from an aging population, which experiences problems with heart valves and congestive heart failure with greater frequency.
EW Analyst's Forecast
Mike Polark
Wolfe Research
Hold → Sell
Price Target
$60
Upside
-14.11%
Wolfe Research downgraded Edwards Lifesciences to Underperform from Peer Perform with a $60 price target. The firm says its core transcatheter aortic valve replacement market share concerns have increased since discovery of FDA information suggesting further deterioration in mortality data at six years in the Partner 3 trial. Also, after another material miss and lower cycle in 2024 that brought the Street closer to Wolfe's prior thinking, the firm's out-year estimate variance versus Street has grown again, the analyst tells investors in a research note.
Joanne Wuensch
Citigroup
Strong Buy
Price Target
$81 → $83
Upside
+12.45%
Matt Miksic
Barclays
Buy
Price Target
$85 → $88
Upside
+24.77%